Found: 54
Select item for more details and to access through your institution.
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 2, p. 394, doi. 10.1093/infdis/jiae192
- By:
- Publication type:
- Article
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 7, p. 941, doi. 10.1093/cid/ciad342
- By:
- Publication type:
- Article
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S77, doi. 10.1093/infdis/jiad246
- By:
- Publication type:
- Article
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S83, doi. 10.1093/infdis/jiad300
- By:
- Publication type:
- Article
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S92, doi. 10.1093/infdis/jiad209
- By:
- Publication type:
- Article
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S101, doi. 10.1093/infdis/jiad285
- By:
- Publication type:
- Article
Immune Status and SARS-CoV-2 Viral Dynamics.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S111, doi. 10.1093/infdis/jiad200
- By:
- Publication type:
- Article
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S117, doi. 10.1093/infdis/jiad287
- By:
- Publication type:
- Article
Long COVID After Bamlanivimab Treatment.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S126, doi. 10.1093/infdis/jiad286
- By:
- Publication type:
- Article
Variant-Specific Viral Kinetics in Acute COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S136, doi. 10.1093/infdis/jiad314
- By:
- Publication type:
- Article
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 2, p. 133, doi. 10.1093/infdis/jiad013
- By:
- Publication type:
- Article
Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 1, p. 64, doi. 10.1093/infdis/jiad060
- By:
- Publication type:
- Article
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 5, p. 658, doi. 10.7326/M22-3428
- By:
- Publication type:
- Article
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e2310039, doi. 10.1001/jamanetworkopen.2023.10039
- By:
- Publication type:
- Article
CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE mAB AGAINST SARS-CoV-2.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 69
- By:
- Publication type:
- Article
SYMPTOM AND VIRAL REBOUND IN UNTREATED COVID-19 INFECTION.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 70
- By:
- Publication type:
- Article
PLASMA ANTIBODY AND N ANTIGEN STATUS PREDICT OUTCOMES IN OUTPATIENTS WITH COVID-19.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 114
- By:
- Publication type:
- Article
TIXAGEVIMAB/CILGAVIMAB IM AND IV FOR COVID-19: A RANDOMIZED CONTROLLED ACTIV-2 TRIAL.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 225
- By:
- Publication type:
- Article
SOLUBLE IMMUNOREGULATORY PROTEINS PREDICTIVE FOR COMORBID EVENTS IN PEOPLE WITH HIV.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 273
- By:
- Publication type:
- Article
POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 286
- By:
- Publication type:
- Article
IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 287
- By:
- Publication type:
- Article
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 3, p. 348, doi. 10.7326/M22-2381
- By:
- Publication type:
- Article
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 4, p. 734, doi. 10.1093/cid/ciac818
- By:
- Publication type:
- Article
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 11, p. 1, doi. 10.1093/ofid/ofac618
- By:
- Publication type:
- Article
Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 10, p. e2238867, doi. 10.1001/jamanetworkopen.2022.38867
- By:
- Publication type:
- Article
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-32551-2
- By:
- Publication type:
- Article
Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.
- Published in:
- Clinical Infectious Diseases, 2022, v. 74, n. 5, p. 857, doi. 10.1093/cid/ciab542
- By:
- Publication type:
- Article
Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 3, p. 1, doi. 10.1093/ofid/ofab570
- By:
- Publication type:
- Article
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2022, v. 74, n. 1, p. 95, doi. 10.1093/cid/ciab212
- By:
- Publication type:
- Article
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 12, p. 1555, doi. 10.1002/jcph.1930
- By:
- Publication type:
- Article
Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 10, p. 1, doi. 10.1093/ofid/ofab423
- By:
- Publication type:
- Article
Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study.
- Published in:
- PLoS ONE, 2021, v. 16, n. 9, p. 1, doi. 10.1371/journal.pone.0254577
- By:
- Publication type:
- Article
Statistical Estimation of the Reproductive Number From Case Notification Data.
- Published in:
- American Journal of Epidemiology, 2021, v. 190, n. 4, p. 611, doi. 10.1093/aje/kwaa211
- By:
- Publication type:
- Article
Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 6, p. 979, doi. 10.1093/cid/ciaa196
- By:
- Publication type:
- Article
Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 8, p. 1764, doi. 10.1093/cid/ciz765
- By:
- Publication type:
- Article
Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, n. 11, p. N.PAG, doi. 10.1093/ofid/ofz434
- By:
- Publication type:
- Article
Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy–mediated Viral Suppression.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 4, p. 676, doi. 10.1093/cid/ciy966
- By:
- Publication type:
- Article
Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 8, p. 1394, doi. 10.1093/cid/ciy716
- By:
- Publication type:
- Article
CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 11, p. N.PAG, doi. 10.1093/ofid/ofy201
- By:
- Publication type:
- Article
Estimating age-specific reproductive numbers-A comparison of methods.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
- Published in:
- Clinical Infectious Diseases, 2018, v. 66, n. 11, p. 1794, doi. 10.1093/cid/cix1131
- By:
- Publication type:
- Article
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 7, p. 853, doi. 10.1093/cid/ciw017
- By:
- Publication type:
- Article
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 4, p. 651, doi. 10.1093/cid/civ327
- By:
- Publication type:
- Article
The Impact of Prior Information on Estimates of Disease Transmissibility Using Bayesian Tools.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0118762
- By:
- Publication type:
- Article
B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.
- Published in:
- EP: Europace, 2014, v. 16, n. 10, p. 1426, doi. 10.1093/europace/euu175
- By:
- Publication type:
- Article